Clinical Trials Directory

Trials / Completed

CompletedNCT00897507

DNA Analysis of Tumor Tissue Samples From Young Patients With Acute Lymphoblastic Leukemia

Single Nucleotide Polymorphisms and Relapse Risk in Standard Risk ALL

Status
Completed
Phase
Study type
Observational
Enrollment
520 (actual)
Sponsor
Children's Oncology Group · Network
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This laboratory study is looking at DNA in tumor tissue samples from young patients with acute lymphoblastic leukemia. DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment

Detailed description

PRIMARY OBJECTIVE: I. To validate significant associations between SNPs and treatment outcome and toxicity on Children's Cancer Group (CCG)-1891 on an independent sample set from a successor CCG study for standard risk acute lymphoblastic leukemia (ALL), CCG-1952. II. To evaluate the role of SNPs in drug metabolizing enzymes and the development of veno-occlusive disease in patients on CCG-1952. III. To evaluate interactions among genotypes and other risk factors for treatment response in a combined data set of CCG-1891 and CCG-1952 with recently developed analytic tools for high dimensional data. IV. To develop predictive models utilizing genetic information obtained in Aim 1.1 and clinical data to predict treatment response and toxicity. OUTLINE: Tumor tissue samples undergo genotype assessment on the Pyrosequencing platform. Contingency tables and X\^2 test performs a univariate analysis of the risk of relapse and genotype, and multivariable analyses using logistic regression. Cox proportional hazards evaluate the risk of relapse given genotype and other confounders. Genotype patterning, classification and regression trees, and multifactor dimensionality reduction evaluates for patterns of single nucleotide polymorphisms associated with toxicity and relapse risk.

Conditions

Interventions

TypeNameDescription
OTHERLaboratory Biomarker AnalysisCorrelative studies

Timeline

Start date
2004-05-13
Primary completion
2016-05-05
First posted
2009-05-12
Last updated
2022-08-15

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00897507. Inclusion in this directory is not an endorsement.